The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2020 | EHA 2020 CLL highlights: CLL14 & CAPTIVATE
Paolo Ghia, MD, of the Università Vita-Salute San Raffaele, Milan, Italy, explores highlights from EHA 2020, including the CLL14 trial (NCT02242942) investigating venetoclax-obinutuzumab in previously untreated, comorbid, chronic lymphocytic leukemia (CLL). The CAPTIVATE study (NCT02910583), which investigated measurable residual disease (MRD)-guided discontinuation and fixed duration therapy with the combination of ibrutinib and venetoclax is also discussed. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
